Berubicin receives FDA Orphan Drug status for gliomas

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Berubicin was granted Orphan Drug Designation by FDA for the treatment of malignant gliomas.

Berubicin is sponsored by CNS Pharmaceuticals Inc.

In the phase I trial of Berubicin to treat glioblastoma under a prior developer, 44% of the patients demonstrated a significant improvement in progression-free survival, and one patient experienced a complete response.

Table of Contents

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login